JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB288315

Human RICTOR knockout A549 cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

RICTOR KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 43 bp deletion in exon 5.

View Alternative Names

AVO3, AVO3 homolog, DKFZp686B11164, KIAA1999, Likely ortholog of mouse TORC2 specific protein AVO3 (S. cerevisiae), MGC39830, PIA, Pianissimo, RICTR_HUMAN, RPTOR independent companion of MTOR complex 2, Rapamycin-insensitive companion of mTOR, TORC2 specific protein AVO3, hAVO3, mAVO3

3 Images
Western blot - Human RICTOR knockout A549 cell lysate (AB288315)
  • WB

Lab

Western blot - Human RICTOR knockout A549 cell lysate (AB288315)

Lane 1 : Wild-type A549 cell lysate 20 μg
Lane 2 : RICTOR knockout A549 cell lysate 20 μg
Lane 3 : HeLa cell lysate 20 μg
False colour image of Western blot : Anti-RICTOR antibody staining at 1 μg/ml, shown in green; Mouse anti-CANX [CANX/1543] (ab238078) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab105469 was shown to bind specifically to RICTOR. A band was observed at 190 kDa in wild-type A549 cell lysates with no signal observed at this size in RICTOR knockout cell line ab277866 (knockout cell lysate ab288315). To generate this image, wild-type and RICTOR knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.

All lanes:

Western blot - Anti-RICTOR antibody (<a href='/en-us/products/primary-antibodies/rictor-antibody-ab105469'>ab105469</a>) at 1 µg/mL

Lane 1:

Wild-type A549 cell lysate at 20 µg

Lane 2:

RICTOR knockout A549 cell lysate at 20 µg

Lane 2:

Western blot - Human RICTOR knockout A549 cell line (<a href='/en-us/products/cell-lines/human-rictor-knockout-a549-cell-line-ab277866'>ab277866</a>)

Lane 3:

HeLa cell lysate at 20 µg

Predicted band size: 192 kDa

Observed band size: 190 kDa

false

Western blot - Human RICTOR knockout A549 cell lysate (AB288315)
  • WB

Lab

Western blot - Human RICTOR knockout A549 cell lysate (AB288315)

Lane 1 : Wild-type A549 cell lysate 20 μg
Lane 2 : RICTOR knockout A549 cell lysate 20 μg
Lane 3 : HeLa cell lysate 20 μg
False colour image of Western blot : Anti-RICTOR antibody [EPR22008] staining at 1/1000 dilution, shown in green; Mouse anti-CANX [CANX/1543] (ab238078) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab219950 was shown to bind specifically to RICTOR. A band was observed at 190 kDa in wild-type A549 cell lysates with no signal observed at this size in RICTOR knockout cell line ab277866 (knockout cell lysate ab288315). To generate this image, wild-type and RICTOR knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.

All lanes:

Western blot - Anti-RICTOR antibody [EPR22008] (<a href='/en-us/products/primary-antibodies/rictor-antibody-epr22008-ab219950'>ab219950</a>) at 1/1000 dilution

Lane 1:

Wild-type A549 cell lysate at 20 µg

Lane 2:

RICTOR knockout A549 cell lysate at 20 µg

Lane 2:

Western blot - Human RICTOR knockout A549 cell line (<a href='/en-us/products/cell-lines/human-rictor-knockout-a549-cell-line-ab277866'>ab277866</a>)

Lane 3:

HeLa cell lysate at 20 µg

Predicted band size: 192 kDa

Observed band size: 190 kDa

false

Sanger Sequencing - Human RICTOR knockout A549 cell lysate (AB288315)
  • Sanger seq

Supplier Data

Sanger Sequencing - Human RICTOR knockout A549 cell lysate (AB288315)

43 bp deletion in exon 5

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 43 bp deletion in exon 5

Disease

Carcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab288315-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human RICTOR knockout A549 cell lysate", "number":"AB288315-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type A549 cell lysate", "number":"AB288315-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
RICTOR
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

RICTOR (Rapamycin-insensitive companion of mTOR) is an important component of the mTOR complex 2 (mTORC2) distinguished by its ability to interact with mTOR (mechanistic target of rapamycin). RICTOR possesses a molecular mass of approximately 192 kDa. You can find RICTOR widely expressed in various tissues including the brain liver and skeletal muscle. Researchers also refer to it as AVO3.
Biological function summary

The protein plays a significant role in cellular growth proliferation and survival. RICTOR forms part of the mTORC2 complex which is important for Akt/PKB phosphorylation. Activation of mTORC2 by RICTOR regulates actin cytoskeleton dynamics and membrane trafficking. This involvement affects the control of cell metabolism and immune responses.

Pathways

RICTOR integrates into the PI3K/Akt signaling pathway influencing cell growth and survival in response to nutrients and growth factors. RICTOR as part of mTORC2 also interacts with proteins such as Sin1 and mLST8 helping regulate PKB/Akt phosphorylation at Ser473. This interaction links RICTOR's function to the insulin signaling pathway which controls aspects of glucose metabolism.

The dysregulation of RICTOR plays a role in cancer progression and metabolic disorders. Alterations in the PI3K/Akt/mTOR signaling pathway can lead to the development of various cancers with RICTOR contributing to tumorigenesis through Akt activation. Additionally aberrant RICTOR expression affects insulin signaling therefore connecting it to diabetes. Through these pathways and conditions RICTOR's interaction with proteins such as mTOR illustrates its relevance in disease mechanisms and therapeutic targets.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com